---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-088365"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2026-08-12T20:14:11+00:00"
generated_at: "2026-08-12T20:15:12.480647+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Longeveron Q2 net loss widens to $6.1M; cash $10.1M into Q4 2026; ELPIS II top-line Sept

## Summary
- Revenue flat at $0.3M; gross profit up 25% to ~$0.2M; G&A up 23% to $3.2M; R&D up 7% to $3.2M.
- Net loss $6.1M vs $5.0M YoY; cash $10.1M expected to fund into Q4 2026; seeks additional financing.
- ELPIS II Phase 2b top-line results for laromestrocel in HLHS expected September 2026; DMC no safety concerns.
- Selected as XPRIZE Healthspan Finalist; receives $1.0M Milestone 2 Award; eligible for up to $81M Grand Prize.
- Three new independent directors added to board; EMA SME status granted in June.

## SEC filing metadata
- accession: 0001213900-26-088365
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2026-08-12T20:14:11+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390026088365/0001213900-26-088365-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390026088365/ea0301757-8k_longeveron.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-088365
- JSON: https://secwatch.observer/filing/0001213900-26-088365.json
- Plain text: https://secwatch.observer/filing/0001213900-26-088365.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.